Interleukin-4 receptor responders

Phase 2Biologic

Interleukin-4 receptor responders is one of 25 biologic programs targeting Seasonal Allergic Rhinitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Seasonal Allergic RhinitisRecruiting

Seasonal Allergic RhinitisPhase 2

Recruiting

Competition

Competitive Landscape

25 competitors in Seasonal Allergic Rhinitis

#DrugCompanyPhaseTrials

Zyrtec

KKenvue Brands

Approved

7 2

Allegra

CChattem

Approved

7 3

Clarinex

OOrganon and Co

Approved

7 4

Flovent

PParatek Pharmaceuticals Inc

Approved

7 5

Claritin

PPerrigo Company

Approved

4 6

Asmanex Hfa

PPerrigo Company

Approved

3 7

Singulair

OOrganon and Co

Approved

3 8

Xyzal

CChattem

Approved

2 9

Kenalog

BBausch Health Americas, Inc.

Approved

—10

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

Recruiting·—·Phase 2·NCT06300203·120 enrolled

A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

Completed·—·Phase 2·NCT05470647·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Interleukin-4 receptor responders. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interleukin-4 receptor responders compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interleukin-4 receptor responders. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Tongren Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBeijing Tongren Hospital

Interleukin-4 receptor responders

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

References

Drug Info

Quick Facts

Related News